Fredrik Scherstén
1 – 10 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clinical impact of intraprocedural stent thrombosis during percutaneous coronary intervention in patients treated with potent p2y12 inhibitors -A validate-swedeheart substudy
(
- Contribution to journal › Article
-
Mark
Characteristics and outcomes in patients with atrial fibrillation and acute coronary syndrome treated with ticagrelor and novel oral anticoagulants
(
- Contribution to journal › Article
- 2020
-
Mark
Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic
(
- Contribution to journal › Article
- 2019
-
Mark
Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure : A multi-centre efficacy study using the Reitan Catheter Pump (RCP)
(
- Contribution to journal › Article
-
Mark
Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management : A prespecified subgroup analysis from VALIDATE-SWEDEHEART
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction
(
- Contribution to journal › Article
- 2018
-
Mark
Blood lactate is a predictor of short-term mortality in patients with myocardial infarction complicated by heart failure but without cardiogenic shock
(
- Contribution to journal › Article
-
Mark
Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care : A retrospective observational study
(
- Contribution to journal › Article
- 2017
-
Mark
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction
(
- Contribution to journal › Article
-
Mark
Bivalirudin versus heparin monotherapy in myocardial infarction
(
- Contribution to journal › Article